Innoviva, Inc. (INVA)
INVA Stock Price Chart
Explore Innoviva, Inc. interactive price chart. Choose custom timeframes to analyze INVA price movements and trends.
INVA Company Profile
Discover essential business fundamentals and corporate details for Innoviva, Inc. (INVA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Oct 2004
Employees
127.00
Website
https://www.inva.comCEO
Pavel Raifeld
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
INVA Financial Timeline
Browse a chronological timeline of Innoviva, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is $0.46, while revenue estimate is $92.01M.
Earnings released on 6 Aug 2025
EPS came in at $0.77 surpassing the estimated $0.57 by +35.09%, while revenue for the quarter reached $100.28M , beating expectations by +10.34%.
Earnings released on 7 May 2025
EPS came in at $0.25 falling short of the estimated $0.29 by -13.79%, while revenue for the quarter reached $88.63M , beating expectations by +7.21%.
Earnings released on 26 Feb 2025
EPS came in at $0.57 surpassing the estimated $0.34 by +67.65%, while revenue for the quarter reached $91.81M , missing expectations by -0.85%.
Earnings released on 6 Nov 2024
EPS came in at $0.02 falling short of the estimated $0.27 by -92.59%, while revenue for the quarter reached $89.51M , beating expectations by +1.54%.
Earnings released on 31 Jul 2024
EPS came in at $0.68 surpassing the estimated $0.24 by +183.33%, while revenue for the quarter reached $103.35M , beating expectations by +38.38%.
Earnings released on 8 May 2024
EPS came in at $0.46 surpassing the estimated $0.17 by +170.59%, while revenue for the quarter reached $80.96M , beating expectations by +19.05%.
Earnings released on 29 Feb 2024
EPS came in at $0.76 surpassing the estimated $0.23 by +230.43%, while revenue for the quarter reached $89.27M , beating expectations by +18.23%.
Earnings released on 1 Nov 2023
EPS came in at $0.98 surpassing the estimated $0.27 by +262.96%, while revenue for the quarter reached $67.26M , missing expectations by -10.93%.
Earnings released on 2 Aug 2023
EPS came in at $0.08 falling short of the estimated $0.26 by -69.23%, while revenue for the quarter reached $80.99M , beating expectations by +17.52%.
Earnings released on 9 May 2023
EPS came in at $0.42 surpassing the estimated $0.23 by +82.61%, while revenue for the quarter reached $76.37M , beating expectations by +23.16%.
Earnings released on 28 Feb 2023
EPS came in at $0.25 falling short of the estimated $0.41 by -39.02%, while revenue for the quarter reached $65.80M , beating expectations by +11.81%.
Earnings released on 9 Nov 2022
EPS came in at $0.60 falling short of the estimated $2.75 by -78.18%, while revenue for the quarter reached $67.26M , beating expectations by +7.44%.
Earnings released on 27 Jul 2022
EPS came in at $0.05 falling short of the estimated $0.55 by -90.91%, while revenue for the quarter reached $108.22M , missing expectations by -49.61%.
Earnings released on 27 Apr 2022
EPS came in at $0.42 surpassing the estimated $0.40 by +5.00%, while revenue for the quarter reached $90.06M , beating expectations by +4.23%.
Earnings released on 9 Feb 2022
EPS came in at $0.55 surpassing the estimated $0.41 by +34.15%, while revenue for the quarter reached $107.68M , beating expectations by +1.23%.
Earnings released on 27 Oct 2021
EPS came in at $0.90 surpassing the estimated $0.43 by +109.30%, while revenue for the quarter reached $97.86M , beating expectations by +28.69%.
Earnings released on 28 Jul 2021
EPS came in at $0.90 surpassing the estimated $0.29 by +210.34%, while revenue for the quarter reached $100.81M , missing expectations by -9.37%.
Earnings released on 28 Apr 2021
EPS came in at $0.84 surpassing the estimated -$0.01 by +8.50K%, while revenue for the quarter reached $85.52M .
Earnings released on 3 Feb 2021
EPS came in at $0.48 surpassing the estimated $0.40 by +20.00%, while revenue for the quarter reached $90.48M , beating expectations by +21.44%.
Earnings released on 28 Oct 2020
EPS came in at $0.46 surpassing the estimated $0.42 by +9.52%, while revenue for the quarter reached $88.69M , missing expectations by -38.10%.
INVA Stock Performance
Access detailed INVA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.